CYP1B1 and myocilin gene mutations in Egyptian patients with primary congenital glaucoma  by Fassad, Mahmoud R. et al.
The Egyptian Journal of Medical Human Genetics (2016) xxx, xxx–xxxHO ST E D  BY
Ain Shams University
The Egyptian Journal of Medical Human Genetics
www.ejmhg.eg.net
www.sciencedirect.comORIGINAL ARTICLECYP1B1 and myocilin gene mutations in Egyptian
patients with primary congenital glaucoma* Corresponding author at: 165 El-Horreya Avenue, El-Hadara, Alexandria 21561, Egypt. Fax: +20 (03) 5842264.
E-mail address: kholeifsf@hotmail.com (S.F. Kholeif).
Peer review under responsibility of Ain Shams University.
http://dx.doi.org/10.1016/j.ejmhg.2016.07.003
1110-8630  2016 Ain Shams University. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Fassad MR et al. CYP1B1 and myocilin gene mutations in Egyptian patients with primary congenital glaucoma. Egypt J M
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.07.003Mahmoud R. Fassad a, Asmaa K. Amin a, Heba A. Morsy a, Noha M. Issa a,
Nader H. Bayoumi b, Sahar A. El Shafei a, Soha F. Kholeif a,*aDepartment of Human Genetics, Medical Research Institute, Alexandria University, Egypt
bDepartment of Ophthalmology, Alexandria Faculty of Medicine, EgyptReceived 2 June 2016; accepted 25 July 2016KEYWORDS
Primary congenital
glaucoma;
PCR/RFLP;
Cytochrome P1B1 gene
mutations;
Myocilin gene mutationAbstract Purpose: Primary congenital glaucoma (PCG) accounts for 26–29% of childhood blind-
ness in Egypt. The identification of disease causing mutations has not been extensively investigated.
We aimed to examine the frequency of CYP1B1 and MYOC mutations in PCG Egyptian patients,
and study a possible genotype/phenotype correlation.
Methods: Ninety-eight patients with PCG diagnosed at the Ophthalmology department of
Alexandria Main University Hospital were enrolled. Demographic and phenotypic characteristics
were recorded. Patients and 100 healthy subjects (control group) were screened for two mutations
in CYP1B1 gene (G61E, R368H) and one mutation in MYOC gene (Gln48His) using polymerase
chain reaction/restriction fragment length polymorphism (PCR/RFLP). Phenotypic characteristics
pertaining to disease severity were compared.
Results: Nineteen patients (19%) with PCG were found positive for one or more of the muta-
tions screened for. Seven patients (7%) were homozygous for the G61E mutation. Ten patients
(10%) were heterozygous; 6 for the G61E mutation, 2 for the R368H mutation and 2 for the
Gln48His mutation. Two patients (2%) were double heterozygotes harboring a R368H as well as
a Gln48His mutation. The most common mutation observed was the G61E in 13 patients; 7
homozygotes and 6 heterozygotes for the mutation. The control group were negative for all muta-
tions screened for.
No significant correlations between the mutations and phenotype severity were detected. A sta-
tistically significant positive correlation however was found between the different mutations and
each of the IOP and the cup/disk ratio.
Conclusion: The current study further endorses the role of CYP1B1 mutations in the etiology of
PCG among Egyptian patients and is the first study to report MYOC gene mutation in Egyptian
patients with PCG.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ed Hum
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Primary congenital glaucoma [PCG (OMIM 231300)] is an
autosomal recessive disorder of the eye with an onset in the
neonatal or early infantile period. It is caused by developmen-
tal defects in the trabecular meshwork and anterior chamber
angle resulting in the obstruction of aqueous outflow leading
to raised intraocular pressure (IOP) [1]. The increased IOP is
responsible for corneal edema, rupture of Descemet’s mem-
brane (Haab Striae), and optic nerve damage which if left
unattended leads to irreversible blindness [2].
The prevalence of PCG varies across the world with the
highest incidence (1:1250) in the Romany population of
Slovakia followed by the Middle East (1:2500) and the lowest
incidence (1:10,000) in the Western population [3–5].
Genetic heterogeneity is the hallmark of PCG. Four differ-
ent loci have been identified: GLC3A on 2p21, GLC3B on
1p36.2, GLC3C on 14q24.3 and GLC3D on 14q24 distal to
GLC3C (2). To date, three genes have been implicated, and
include cytochrome P450, subfamily I, polypeptide 1
(CYP1B1), latent transforming growth factor b binding pro-
tein 2 (LTBP2) and myocilin (MYOC) [6]. Mutations in the
CYP1B1 (OMIM 601771), located in the GLC3A locus, is
the most common genetic cause of PCG worldwide. In addi-
tion, myocilin gene (MYOC, OMIM 601652) on 1q23 has been
implicated in the pathogenesis of some cases of PCG either
independently or in association with CYP1B1 mutations [7].
PCG accounts for 26–29% of childhood blindness in Egypt
[8]. Identification of disease-causing mutations has not been
extensively studied. This study was conducted to examine
the frequency of CYP1B1 and MYOC mutations in
PCG Egyptian patients. In addition, genotype- phenotype
correlation was attempted.2. Patients and methods
The study protocol adhered to the Declaration of Helsinki
guidelines and was approved by the Ethics committees of the
Faculty of Medicine and the Medical Research Institute,
University of Alexandria. An informed consent was signed
by the legal guardian of all participants.
2.1. Patients
Ninety-eight patients presenting with and operated upon for
PCG at the Ophthalmology department of Alexandria Main
University Hospital were enrolled. All patients were examined
and operated upon by a single surgeon (NB). A control group
of 100 healthy subjects screened for the absence of any ocular
disease or abnormality was included for the molecular part of
the study. Examination of patients in Alexandria Main
University hospital follows a standard protocol previously
described by the authors [9,10]. PCG was diagnosed clinically
when a patient presented with an enlarged cornea and/or cor-
neal haze with an elevated IOP under inhalational general
anesthesia(GA) [11] and optic nerve cupping in the absence
of any associated ocular or systemic anomalies or secondary
conditions known to be associated with or to cause glaucoma.
Owing to the known effect of inhalational anesthetics on
measured IOP [12], PCG was diagnosed also if there was aPlease cite this article in press as: Fassad MR et al. CYP1B1 and myocilin gene muta
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.07.003significant difference of more than 5 mmHg in the measured
IOP between the 2 eyes [11], or if successive examination under
anesthesia (EUA) demonstrated progression in any of mea-
sured ocular biometric parameters beyond the normal rate of
growth of the eye irrespective of the measured absolute value
of the IOP [9–12]. Any patient with a suspiciously low initial
IOP under GA was followed up for several weeks to document
rapid progression of the cup/disk ratio or the axial length
beyond what is expected for that age group. When this was
demonstrable, the diagnosis of PCG was established and the
patient managed accordingly. Classification of patients into
mild, moderate or severe was based on clinical findings [13].
2.2. Molecular study
Peripheral venous blood samples were withdrawn from both
98 patients and 100 healthy volunteer donors (control).
DNA extraction was performed using Qiamp DNA Blood
Mini kit (Qiagen, Germany) according to the manufacturer‘s
protocol. Screening for 2 mutations in CYP1B1 (G61E,
R368H) and one mutation in MYOC (Gln48His) was accom-
plished using PCR/RFLP. The coding regions (1.6 Kb) span-
ning exons II and III of CYP1B1 gene were amplified from
genomic DNA of both patients and control samples using
three sets of primers as previously described (Table 1)
[14,15]. When no mutation was found in CYP1B1 gene, as well
as in patients with heterozygous mutations, amplification of
coding region of MYOC gene encompassing Gln48His muta-
tion was carried out using previously published primer
sequence [7] (Table 1).
2.3. Statistical analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS ver.20 Chicago, IL, USA). Comparing quanti-
tative variables between different genetic mutations was done
using Kruskal Wallis test. A level of significance of 0.05 was
used.
2.4. Results
The study was conducted on 98 (58 males, 40 females) patients
with PCG. Consanguinity was present in 49% of the studied
group. A positive family history was present in 12 patients
(12%) of the studied group. The demographic and clinical
characteristics of the patients are demonstrated in (Table 2).
PCR-RFLP analyses were performed for CYP1B1 muta-
tions (G61E, R368H) and MYOC mutation (Gln48His). Of
the 98 patients examined, 19 patients (19%) with PCG were
found positive for one or more of the mutations screened
for. Seven patients (7%) were homozygous for the G61E muta-
tion. Ten patients (10%) were heterozygous; 6 for the G61E
mutation, 2 for the R368H mutation and 2 for the Gln48His
mutation. Two patients (2%) were double heterozygotes har-
boring a R368H as well as a Gln48His mutation.
Among 19 patients carrying a mutation, the most common
mutation observed was the G61E present in 13 patients,
accounting for 68.5% of mutations screened for. The fre-
quency of the heterozygous R368H mutation, Gln48His muta-
tion was as well as the double heterozygote R368H/Gln48His
mutation was 10.5% for each.tions in Egyptian patients with primary congenital glaucoma. Egypt J Med Hum
Table 1 PCR/RFLP for identification of mutations in CYPIBI and MYOC genes.
Gene Mutation PCR primers PCR product (bp) Restriction enzyme Digest normal Digest mutant
CYP1B1 G528A 50-tctccagagagtcagctccg-30 786 Taq I 627, 84, 75 318,309,84,75
(G61E) 50-gggtcgtcgtggctgtag -3’
G1449A 50-tcccagaaatattaatttagtcactg -30 885 Taa I 507, 200, 178 507, 352, 26
(R368H) 50-tatggagcacacctcacctg-30
MYOC G144T 50-ggctggctccccagtatatat-30 334 AccI 271, 63 334
(Gln48His) 50-gatgactgacatggcctgg-30
CYPIBI: Cytochrome P1B1.
MYOC: Myocilin.
PCR: polymerase chain reaction.
bp: base pair.
Table 2 Demographic data and clinical characteristics of the
patients.
The demographic data, clinical characteristics
PCG cases
Patients, n (%) [98, (100)]
Male 58 (67)
Female 40 (33)
Eyes, n (%) [144, (100)]
Right eye only 25 (25.5)
Left eye only 27 (27.6)
Bilateral 46 (46.9)
Age at onset of PCG, mean (±SD,
range, median) months
3.8 (±4.3, 0–25, 3)
Clinical severity (144 eyes)
Mild 125 (86.8)
Moderate 19 (13.2)
Severe 0 (0)
Clinical characteristics at presentation mean (± SD, range,
median)
Intraocular pressure (mmHg) 18.1 (±6.3, 4–40, 18)
Corneal diameter (mm) 13.1 (±0.9, 10–16, 13)
Axial length (mm) 23.57 (±2.25, 19.35–
32.87, 23.24)
Cup/disk ratio 0.4 (±0.3, 0–1, 0.3)
CYP1B1 and myocilin gene mutations in patients with primary congenital glaucoma 3MYOC gene mutation Gln48His was observed in a
heterozygous state in 4 patients of the 91 screened for the
mutation (4.4%); 2 of these were double heterozygotes harbor-
ing a R368H as well. None of the control group were positive
for any of the mutations screened.
The ophthalmologic findings in patients with unilateral/
bilateral glaucoma who were positive for one of the mutations
screened for are presented in (Tables 3 and 4) respectively.
No significant correlations between the mutations and
phenotypic severity were detected. A statistically significant
positive correlation however was found between the different
mutations and each of the IOP and the cup/disk ratio
(Table 5).
3. Discussion
This is the first extensive genetic study demonstrating the role
of CYP1B1 and MYOC gene mutations in Egyptian patientsPlease cite this article in press as: Fassad MR et al. CYP1B1 and myocilin gene mutat
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.07.003with PCG. Our cohort included 98 patients from 98 families
as well as 100 control. The patients and control group were
screened for 2 mutations in the CYP1B1 gene which have been
implicated in the etiology of PCG in the Arab, Middle Eastern
and Mediterranean Countries [16–21]. Several reports have
documented the role of MYOC gene mutations in the etiology
of PCG when no pathogenic mutations were found in the
CYP1B1 gene [21,22]. These reports have prompted us to look
for MYOC gene mutations in patients who were heterozygous
or had no pathogenic mutation in the CYP1B1 gene.
Screening for mutations in the CYP1B1 gene and the
MYOC gene revealed that 19% of the patients enrolled in this
study carried a mutation causing PCG. CYP1B1 is major con-
tributing gene for PCG. In the present study 17% of patients
with PCG carried a mutation in the CYP1B1 gene which is
lower than the prevalence of CYP1B1 mutations reported in
Saudi Arabia (79.4%) [16] and Lebanon (33%) [17]. This
may be explained by the fact that 82.6% of the patients
included in this study had a mild phenotype in contrast to
patients from Saudi Arabia and Lebanon who had severe phe-
notypes. Moreover, forty-two patients (42.8%) in this study
had unilateral glaucoma. In a study conducted on cases with
unilateral glaucoma in Saudi Arabia, none of the patients were
found to harbor a CYP1B1 gene mutation [18]. Variation in
sample size could be another explanation as the Saudi and
Lebanese studies included fewer patients than the current
study. The presence of disease causing mutations other than
those screened for in this study may be another explanation.
Although the frequency of patients with PCG harboring a
mutation was lower in the present study compared to other
studies, yet, within the group of patients harboring a mutation
the frequency of the different mutations screened for was com-
parable to that reported in the literature. In the present study,
the G61E mutation was the most frequently encountered
mutation (68.5%) within the group of patients harboring a
mutation. This is expected as G61E mutation is a reported
founder mutation in Arabs and Middle Eastern populations.
The results of the present study are in accordance with the
results reported by Badeeb et al. (2014) [16] who found the
G61E mutation in 66.6% of Saudi patients harboring a muta-
tion. Moreover, the G61E mutation has been reported to be
the commonest mutation in Lebanese patients (33%) [17], Ira-
nian patients (32%) [20] as well as Kuwaiti patients (47%) [19]
with PCG.
In the present study R368H mutation was detected in a
heterozygous form in four patients (21%) in the mutation pos-
itive group. Among patients with PCG harboring a mutation,ions in Egyptian patients with primary congenital glaucoma. Egypt J Med Hum
Table 3 Ophthalmological findings in patients with unilateral glaucoma positive for a mutation in the CYB1 gene or Myocilin gene.
Patient
ID
Age at diagnosis
(months)
Sex Ophthalmology findings Result of Mutations screened for by
PCR/RFLP
IOP Corneal
diameter
Corneal
clarity
Axial
length
C/D
ratio
16 2 Male 18 13 Haze 21.44 0.5 Homozygote for G61E
42 1 Female 15 13 Haze 21.12 0.1 Homozygote for G61E
69 2 Female 32 12.5 Edema 21.56 0.5 Homozygote for G61E
51 3 Male 14 12.5 Edema 22.75 0.2 Heterozygote for G61E
68 1 Male 24 14 Haze 22.55 0.6 Heterozygote for G61E
76 2 Male 18 11 Edema 21.67 0.1 Heterozygote for G61E
106 8 Male 24 14 Edema 24.09 0.3 Heterozygote for G61E
56 12 Male 10 13 Clear 22.89 0.1 Heterozygote for R368H
64 6 Male 10 13 Edema 22.28 0 Heterozygote for R368H
47 4 Male 16 13 Edema 23.3 0.1 Heterozygote for Gln48His
Abbreviations: IOP: intraocular pressure, C/D: cup/disk.
PCR: polymerase chain reaction.
RFLP: restriction fragment length polymorphism.
Table 4 Ophthalmological findings in patients with bilateral glaucoma positive for a mutation(s) in the CYB1 gene and/or Myocilin
gene.
Patient
ID
Age at diagnosis
(months)
Sex Ophthalmology findings Result of Mutations screened for
by PCR/RFLP
IOP Corneal
diameter
Corneal
clarity
Axial Length C/D
Ratio
OD OS OD OS OD OS OD OS OD OS
1 2 Female 18 17 12.5 13.5 Haze Scar 21.53 23.11 0.9 0.8 Homozygote for G61E
57 11 Male 16 18 14 15 Edema 25.7 26.61 0.8 0.7 Homozygote for G61E
58 2 Male 9 16 14 13 Clear Hazy 23.08 21.55 0.3 0.3 Homozygote for G61E
97 1 Male 18 24 12 13 Edema 21.54 22.48 0.4 0.4 Homozygote for G61E
71 3 Female 22 18 14 13.5 Haze Haze 22.45 22.16 0.3 0.3 Heterozygote for G61E
107 1 Male 18 17 12.5 12 Edema 21.09 20.22 0 0.2 Heterozygote for G61E
52 3 Male 4 4 13.5 13 Clear Clear 25.35 23.28 0.5 0.2 Heterozygote for Gln48His
61 5 Male 17 36 14 14.5 Haab Straie 25.41 25.58 0.8 0.5 Heterozygote for both R368H
and Gln48His
70 8 Female 18 26 14 14 Edema 25.01 26.47 0.9 0.9 Heterozygote for both R368H
and Gln48His
Abbreviations: IOP: intraocular pressure, OD: right eye, OS: left eye, C/D: cup/disk.
PCR: polymerase chain reaction.
RFLP: restriction fragment length polymorphism.
Table 5 Correlation of mutations with IOP and CD ratio.
Homozygote
G61E
Heterozygote
G61E
Heterozygote
R386H
Heterozygote
Gln48His
Heterozygotes for
both R368H and Gln48His
(p)
IOP p= .02*
Median 18 18 10 4 22
(min–max) 9–32 14–24 10–10 4–16 17–36
C/D ratio p= .006*
Median 0.5 0.25 .05 0.1 0.85
(min–max) 0.1–0.9 0–0.6 0–0.1 0.1–0.1 0.5–0.9
By Kruskal Wallis test.
Abbreviations: IOP: intraocular pressure, C/D: cup/disk.
* statistically significant.
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CYP1B1 and myocilin gene mutations in patients with primary congenital glaucoma 5Chitsazian et al. 2007 [20] found the R368H mutation in 15%
of Iranian patients whereas Giuffre’ 2011 [21] detected the
R368H mutation in 8% of Italian patients. Although the fre-
quency of the R368H mutation in the present study is higher
than that reported in the aforementioned studies, yet, it is quite
similar to that reported by Milla´ et al. 2103 [22] who found
that 20% of Spanish patients with PCG possessed the
R368H. The North coast of Egypt particularly Alexandria
located on the Mediterranean Sea is likely to share genes of
other Mediterranean countries, as it was a host to many differ-
ent communities during the colonial period, including Greeks,
Italians, Syrians, Jews and Armenians. The potential role of
CYP1B1 has been well documented in PCG cases worldwide.
CYP1B1 gene participates in the normal development and
functioning of the eye by metabolizing essential molecules that
are probably used in a signaling pathway [23]. Its presence in
the inner ciliary and lens epithelia appears to be necessary
for normal development of the trabecular meshwork and in
regulating intraocular pressure [24]. The highly conserved
G61E mutation is adjacent to the N-terminal proline-rich
region of CYP1B1 and is likely to affect the proper protein
function and result in disease manifestation [14]. R368H, maps
to helix K, which is one of the highly conserved core structures
(CCSs). The CCSs are suspected to be involved in proper pro-
tein folding and in active heme binding [25].
The presence of mutations in CYP1B1 gene does not
account for all cases with PCG worldwide. Mutations in the
MYOC gene have been implicated in the etiology of not only
POAG (primary open angle glaucoma) [26] and JOAG (juve-
nile open angle glaucoma) [27] but also in PCG [7]. Four of
the ninety-one patients tested (4.4%) were heterozygous for
the G144T mutation, of these two were heterozygote for both
R368H and Gln48His mutations. This is the first report of
MYOC gene mutations in Egyptian patients with PCG.
MYOC gene mutations have been reported as a disease caus-
ing mutation in patients with PCG in the Mediterranean
region, where Giuffre’ 2011 [21] reported that a frequency of
4.2% among Italian patients with PCG and Milla´ et al. 2103
[22] reported a frequency of 4.8% among Spanish patients with
PCG implying that the Egyptian population is an admixture of
ethnic background. A potential digenic mechanism in a PCG
case resulting from the simultaneous involvement of mutant
alleles of MYOC and CYP1B1 has been previously proposed
[7]. MYOC gene encode myocilin protein, which is found in
the trabecular meshwork and the ciliary body of the eye.
Mutations in the olfactomedin domain of myocilin (myoc-
OLF) are the strongest link to inherited primary open angle
glaucoma. In this recently identified protein misfolding disor-
der, aggregation-prone disease variants of myocilin hasten
glaucoma-associated elevation of intraocular pressure, leading
to vision loss [28].
The present study demonstrated no significant correlations
between the mutations screened for and phenotypic severity.
Our results are in accordance with those of de Melo et al.
2015 [29] who reported a lack of genotype-phenotype correla-
tion of the demographic and clinical traits to CYP1B1 muta-
tions in PCG. Yet, Panicker et al. 2004 [30] and Berraho
et al. 2015 [31] have reported a correlation between disease
severity and different pathogenic mutations. In the present
study the positive correlation found between the different
mutations and each of the IOP and the cup/disk ratio has been
previously reported [31,32].Please cite this article in press as: Fassad MR et al. CYP1B1 and myocilin gene mutat
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.07.003In conclusion, this is the first extensive study addressing the
role CYP1B1 and MYOC gene mutations in the etiology of
PCG among Egyptians. Our results further endorse the role
of CYP1B1 mutations in the etiology of PCG among Egyptian
patients and ours is the first study to reportMYOC gene muta-
tion in Egyptian patients with PCG. The presence of patients
with PCG in whom no mutations in either the CYP1B1 or
MYOC genes were detected suggests the presence of other dis-
ease causing mutations implying marked genetic heterogeneity
of PCG in Egypt.
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